Pharmacokinetics of Ciprofloxacin in Neonates
Conditions
Keywords
Ciprofloxacin, Neonates, Gram negative infection
Brief summary
Phase I, open-label study to evaluate the pharmacokinetics, tolerability and short-term safety of ciprofloxacin in neonates with suspected (or proven) Gram Negative infection. Objectives: To evaluate the multiple-dose pharmacokinetics of ciprofloxacin in neonates and young infants (24 - 52 weeks postmenstrual age) with suspected or proven Gram Negative infection. To evaluate the tolerability and describe short-term safety of ciprofloxacin in neonates and young infants with suspected (or proven) Gram Negative infection. To describe the clinical outcomes of neonates treated with ciprofloxacin
Detailed description
This study is part of TINN 'Treat Infections in Neonates' a comprehensive project that is evaluating the safety of ciprofloxacin and how it is tolerated by neonates. Ciprofloxacin is an antibiotic that has been used for many years in newborn babies and infants less than 3 months old to treat bacteria that are resistant to other antibiotics. Ciprofloxacin is unlicensed for this age group. The European Medicines Agency and WHO have prioritised research about this drug. The TINN consortium aims to conduct the work required for a license (marketing authorization) in newborn babies and infants less than 3 months old. The aim of this study is to describe how newborn babies and young infants deal with this medicine. Blood samples will be taken at the beginning of the course of antibiotics and at the end. A minimal amount of blood will be required (less than half a teaspoon) in total and collected by staff experienced in blood sampling from neonates in a way that causes the least disruption to the baby. The levels of ciprofloxacin in the blood will be measured. The levels will be used to work out how quickly the body gets rid of the medicine. This will allow recommendations about the best dose and how often the medicine should be given. We aim to recruit 50 neonates and infants under the age of 3 months who have been prescribed Ciprofloxacin as inpatients for suspected or proven infection. They will be recruited over 2 years from the neonatal unit at Liverpool Women's NHS Foundation Trust and Alder Hey Children's NHS Foundation Trust. Consent will be requested for babies to have more detailed investigation to see if there if genetic factors affect the way the body handles ciprofloxacin.
Interventions
PROCEDURECollection of biological samples
Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7). Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces
Sponsors
University of Liverpool
Liverpool Women's NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
24 Weeks to 52 Weeks
Healthy volunteers
No
Inclusion criteria
* Receiving ciprofloxacin following clinical decision by attending physician
Exclusion criteria
* Likely not to survive 48 hours in the judgement of attending physician * Ciprofloxacin commenced before 5th day of life
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters | 6 weeks | Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters \[maximum concentration, clearance, area under the curve (0-tau)\], their relationship with selected covariates their interindividual variability (CV%). Covariate analysis will include postmenstrual age, gestational age, postnatal age, weight, and serum creatinine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK variables | 6 weeks | PK variables, including apparent volume of distribution and half life. |
| Tolerability | 6 weeks | Withdrawal due to lack of tolerability |
| Safety | 6 Weeks | Adverse events (AEs) and serious adverse events (SAEs). |
| Clinical/microbiological outcomes | 6 Weeks | Outcome of treatment episodes (clinical and microbiological) |
Countries
United Kingdom
Outcome results
None listed